Neuronetics Analyst Ratings
JMP Securities Maintains Neuronetics(STIM.US) With Buy Rating, Cuts Target Price to $3
CCORF Maintains Neuronetics(STIM.US) With Buy Rating, Cuts Target Price to $3
William Blair Downgrades Neuronetics(STIM.US) to Hold Rating
Neuronetics Analyst Ratings
Neuronetics Analyst Ratings
Strong Buy Rating for Neuronetics Backed by Solid Financials and Growth Prospects
Buy Rating on Neuronetics: Solid Fundamentals and Growth Despite Challenges
Buy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD Market
Neuronetics Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for Neuronetics (STIM)
Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Marinus (MRNS) and Gritstone Oncology (GRTS)
Neuronetics Stock Receives Buy Rating From Canaccord Genuity Amid Strong Q4 Performance and Positive Outlook
Positive Q3 Results and Commercial Initiatives Drive Plovanic's Buy Rating on Neuronetics (STIM)
Promising Growth and Strategic Advancements: A Buy Rating for Neuronetics
Neuronetics (STIM) Receives a Buy From JMP Securities
JMP Securities Reiterates Market Outperform on Neuronetics, Maintains $12 Price Target
Analysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Neuronetics (STIM)
Canaccord Genuity Adjusts Price Target on Neuronetics to $7 From $9, Maintains Buy Rating
JMP Securities Reiterates Market Outperform on Neuronetics, Maintains $12 Price Target
No Data
No Data